Patients ( n = @ ) were randomized ( @:@ ) to receive rituximab ( @ mg/m ( @ ) intravenously -LSB- I.V. -RSB- weekly for @ weeks ) either as a single agent or with bevacizumab ( @ mg/kg I.V. on days @ and @ ) .